Abiopharma

CAPR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

BABA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead the Alibaba Class Action Lawsuit

Register of shareholders, changes and capital status – exercise of the company’s employee warrants

WeTouch Secures Singapore Commercial Outdoor Project, Demonstrating Whole-Product Customization and Expanding Southeast Asia Footprint

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray

FitLife Brands Announces Second Quarter Earnings Call

INTU INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Intuit Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Clinical trial NCT06903702 updates: 1. status: NOT_YET_RECRUITING → WITHDRAWN 2. enrollment: 100 → 0 participants 3. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07742475: start date: 2026-07-01 → 2026-09-01.

Clinical trial NCT06773936: start date: 2026-05-15 → 2026-04-13.

Clinical trial NCT07294872 updates: 1. start date: 2026-05-08 → 2026-12-08 2. primary completion date: 2026-09-20 → 2027-09-20

Clinical trial NCT03952559 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-05-01 → 2026-05-22

Clinical trial NCT06006403 updates: 1. status: RECRUITING → COMPLETED 2. start date: 2023-08-31 → 2024-03-28 3. completion date: 2026-08-31 → 2025-12-31 4. primary completion date: 2025-12-31 → 2025-09-25 5. enrollment: 36 → 5 participants 6. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07216482 updates: 1. completion date: 2027-03-01 → 2026-11-05 2. primary completion date: 2026-12-02 → 2026-08-12

Clinical trial NCT04967833 updates: 1. completion date: 2026-04-22 → 2029-04-22 2. primary completion date: 2025-12-22 → 2027-12-22